Published in PLoS One on October 19, 2011
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity (2012) 3.77
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J Infect Dis (2012) 2.89
Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol (2012) 2.74
Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol (2013) 2.09
Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol (2013) 1.69
The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies. PLoS Pathog (2013) 1.67
Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. Cell Host Microbe (2014) 1.57
Distinct germinal center selection at local sites shapes memory B cell response to viral escape. J Exp Med (2015) 1.50
Identification and characterization of the constituent human serum antibodies elicited by vaccination. Proc Natl Acad Sci U S A (2014) 1.50
Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J Virol (2013) 1.49
HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol (2012) 1.39
High Inter-Individual Diversity of Point Mutations, Insertions, and Deletions in Human Influenza Virus Nucleoprotein-Specific Memory B Cells. PLoS One (2015) 1.37
Tools to therapeutically harness the human antibody response. Nat Rev Immunol (2012) 1.30
Molecular deconvolution of the monoclonal antibodies that comprise the polyclonal serum response. Proc Natl Acad Sci U S A (2013) 1.26
Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees. J Virol (2013) 1.26
Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J Virol (2014) 1.20
Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation. Front Immunol (2014) 1.19
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodies. Science (2015) 1.14
H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol (2013) 1.14
HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol (2012) 1.13
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. Cell Host Microbe (2014) 1.11
Progress in HIV-1 vaccine development. Curr Opin HIV AIDS (2013) 1.09
Viral receptor-binding site antibodies with diverse germline origins. Cell (2015) 1.09
An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol (2014) 1.06
Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. Vaccine (2015) 0.96
Progress in HIV-1 vaccine development. J Allergy Clin Immunol (2014) 0.94
Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat Med (2016) 0.93
A critical question for HIV vaccine development: which antibodies to induce? Science (2014) 0.91
Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum. PLoS One (2012) 0.89
Focused antibody response to influenza linked to antigenic drift. J Clin Invest (2015) 0.89
Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. MBio (2016) 0.88
H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. J Immunol (2015) 0.86
Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage. Proteins (2015) 0.86
A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of antibody epitopes for HIV-1 Env immunogen design. J Virol (2013) 0.85
Implications of broadly neutralizing antibodies in the development of a universal influenza vaccine. Curr Opin Virol (2016) 0.85
Humans and ferrets with prior H1N1 influenza virus infections do not exhibit evidence of original antigenic sin after infection or vaccination with the 2009 pandemic H1N1 influenza virus. Clin Vaccine Immunol (2014) 0.83
Novel universal influenza virus vaccine approaches. Curr Opin Virol (2016) 0.82
Deep Sequencing of Influenza A Virus from a Human Challenge Study Reveals a Selective Bottleneck and Only Limited Intrahost Genetic Diversification. J Virol (2016) 0.82
Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr Opin HIV AIDS (2015) 0.82
Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. MBio (2016) 0.81
Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain. Nat Med (2016) 0.81
HIV vaccine research and discovery in the nonhuman primates model: a unified theory in acquisition prevention and control of SIV infection. Curr Opin HIV AIDS (2013) 0.80
Immunogenic Stimulus for Germline Precursors of Antibodies that Engage the Influenza Hemagglutinin Receptor-Binding Site. Cell Rep (2015) 0.79
Cross-reactive responses to modified M1₅₈-₆₆ peptides by CD8⁺ T cells that use noncanonical BV genes can describe unknown repertoires. Eur J Immunol (2012) 0.79
Significant cross reactive antibodies to influenza virus in adults and children during a period of marked antigenic drift. BMC Infect Dis (2014) 0.79
Ex vivo analysis of human memory B lymphocytes specific for A and B influenza hemagglutinin by polychromatic flow-cytometry. PLoS One (2013) 0.78
Random yet deterministic: convergent immunoglobulin responses to influenza. Trends Microbiol (2014) 0.77
Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease? Curr Opin Immunol (2016) 0.77
Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev (2017) 0.77
Efficient generation of monoclonal antibodies from single rhesus macaque antibody secreting cells. MAbs (2015) 0.76
Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies. Immunol Rev (2017) 0.76
The effective rate of influenza reassortment is limited during human infection. PLoS Pathog (2017) 0.75
Globular Head-Displayed Conserved Influenza H1 Hemagglutinin Stalk Epitopes Confer Protection against Heterologous H1N1 Virus. PLoS One (2016) 0.75
Tissue memory B cell repertoire analysis after ALVAC/AIDSVAX B/E gp120 immunization of rhesus macaques. JCI Insight (2016) 0.75
Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies. Curr Opin Immunol (2016) 0.75
Proteomic Analysis of Pemphigus Autoantibodies Indicates a Larger, More Diverse, and More Dynamic Repertoire than Determined by B Cell Genetics. Cell Rep (2017) 0.75
CryoEM Structure of an Influenza Virus Receptor-Binding Site Antibody-Antigen Interface. J Mol Biol (2017) 0.75
Identification of common molecular subsequences. J Mol Biol (1981) 130.53
Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res (1998) 106.16
Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res (1998) 96.63
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Influenza-associated hospitalizations in the United States. JAMA (2004) 18.23
Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol (2009) 12.13
Updating the accounts: global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med (2002) 11.85
Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med (1953) 11.41
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature (2008) 10.80
Disquisitions of Original Antigenic Sin. I. Evidence in man. J Exp Med (1966) 9.26
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One (2008) 6.98
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep (2009) 5.80
Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1984) 5.49
Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science (2010) 5.13
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis (1999) 4.67
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol (2008) 4.45
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Transmission of the common cold to volunteers under controlled conditions. I. The common cold as a clinical entity. AMA Arch Intern Med (1958) 3.83
Different B cell populations mediate early and late memory during an endogenous immune response. Science (2011) 3.63
Inter- and intraclonal diversity in the antibody response to influenza hemagglutinin. J Exp Med (1985) 3.54
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Disquisitions on Original Antigenic Sin. II. Proof in lower creatures. J Exp Med (1966) 3.36
Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat Protoc (2009) 3.30
Viral shedding and clinical illness in naturally acquired influenza virus infections. J Infect Dis (2010) 3.29
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol (2009) 2.80
High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J Virol Methods (2009) 2.75
Role of BCR affinity in T cell dependent antibody responses in vivo. Nat Immunol (2002) 2.63
SoDA: implementation of a 3D alignment algorithm for inference of antigen receptor recombinations. Bioinformatics (2005) 2.41
Swine outbreak of pandemic influenza A virus on a Canadian research farm supports human-to-swine transmission. Clin Infect Dis (2011) 2.28
Variation and infectivity neutralization in influenza. Immunology (2006) 2.23
Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med (2010) 2.21
Very low affinity B cells form germinal centers, become memory B cells, and participate in secondary immune responses when higher affinity competition is reduced. J Exp Med (2002) 2.07
Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol (2009) 1.94
Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines (2009) 1.83
Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J Immunol (1966) 1.82
Universal influenza A vaccine: optimization of M2-based constructs. Virology (2005) 1.76
Analysis of the virus-specific and nonspecific B cell response to a persistent B-lymphotropic gammaherpesvirus. J Immunol (2000) 1.64
Multiple infections with seasonal influenza A virus induce cross-protective immunity against A(H1N1) pandemic influenza virus in a ferret model. J Infect Dis (2010) 1.61
Update: influenza activity--United States, April-August 2009. MMWR Morb Mortal Wkly Rep (2009) 1.61
V region gene usage and somatic mutation in the primary and secondary responses to influenza virus hemagglutinin. J Immunol (1990) 1.49
Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries. PLoS Pathog (2010) 1.46
Update on influenza A (H1N1) 2009 monovalent vaccines. MMWR Morb Mortal Wkly Rep (2009) 1.45
Expression of the immunoglobulin VH gene 51p1 is proportional to its germline gene copy number. J Clin Invest (1996) 1.35
Influenza virus. Curr Protoc Immunol (2001) 1.35
The BALB/c secondary response to the Sb site of influenza virus hemagglutinin. Nonrandom silent mutation and unequal numbers of VH and Vk mutations. J Immunol (1990) 1.30
Chiropteran types I and II interferon genes inferred from genome sequencing traces by a statistical gene-family assembler. BMC Genomics (2010) 1.01
Morphological and biochemical characterization of influenza vaccines commercially available in the United Kingdom. Vaccine (1994) 0.97
The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet (2006) 20.76
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98
Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med (2003) 10.82
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science (2005) 9.04
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med (2009) 7.82
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol (2008) 7.54
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell (2002) 6.95
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol (2009) 5.99
Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol (2010) 5.92
Jmjd1a and Jmjd2c histone H3 Lys 9 demethylases regulate self-renewal in embryonic stem cells. Genes Dev (2007) 5.79
Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell (2010) 5.77
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol (2008) 5.69
Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature (2012) 5.44
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature (2013) 5.35
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Acute HIV-1 Infection. N Engl J Med (2011) 4.84
Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity (2013) 4.82
ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science (2004) 4.81
Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. J Exp Med (2009) 4.79
Medicine. The need for a global HIV vaccine enterprise. Science (2003) 4.70
Experimental observation of the quantum anomalous Hall effect in a magnetic topological insulator. Science (2013) 4.69
Comprehensive analysis of heterochromatin- and RNAi-mediated epigenetic control of the fission yeast genome. Nat Genet (2005) 4.66
Expression profile matrix of Arabidopsis transcription factor genes suggests their putative functions in response to environmental stresses. Plant Cell (2002) 4.58
TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages. Nat Immunol (2010) 4.56
Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res (2011) 4.55
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol (2005) 4.54
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol (2011) 4.06
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Evolution of the mammalian transcription factor binding repertoire via transposable elements. Genome Res (2008) 3.76
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol (2012) 3.69
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A (2011) 3.51
Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol (2009) 3.36
Clinical identifiers of complicated Staphylococcus aureus bacteremia. Arch Intern Med (2003) 3.31
HIV-1 neutralizing antibodies: understanding nature's pathways. Immunol Rev (2013) 3.30
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology (2006) 3.26
Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity (2010) 3.25
Sall4 interacts with Nanog and co-occupies Nanog genomic sites in embryonic stem cells. J Biol Chem (2006) 3.24
Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med (2013) 3.24
Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med (2005) 3.21
Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med (2005) 3.19
Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc Natl Acad Sci U S A (2009) 3.19
Identifying differential expression in multiple SAGE libraries: an overdispersed log-linear model approach. BMC Bioinformatics (2005) 3.12